[1]
|
M. Atmaca, M. Kuloglu, E. Tezcan, B. Ustundag and N. Kilic, “Nizatidine for the Treatment of Patients with Quetiapine-Induced Weight Gain,” Hum Psychopharmacol, Vol. 19, No. 1, 2004, pp. 37-40. doi:10.1002/hup.477
|
[2]
|
PRNewswire, “Eli Lilly and Company and Reliant Pharmaceuticals Announce Agreement for U.S. Sales and Marketing Rights to Axid (R),” Indianapolis, September 7, 2000.
|
[3]
|
F. Parente and G. B. Porro, “Acid Inhibitory Characteristics of Nizatidine in Man: An Overview,” Scandinavian Journal of Gastroenterology, Vol. 29, No. s206, 1994, pp. 3-7. doi:10.3109/00365529409091413
|
[4]
|
The United States Pharmacopoeia 32 National Formulary 27. (USP)
|
[5]
|
European Pharmacopoeia 4.2, Council of Europe, 2002, pp. 2737-2739.
|
[6]
|
U. D. Neue, D. McCabe, V. Ramesh, H. Pappa, J. DeMuth, “Transfer of HPLC Procedures to Suitable Columns of Reduced Dimensions and Particle Sizes,” Pharmacopeial Forum, Vol. 35, No. 6, 2009, pp.1622-1626.
|
[7]
|
International Conference on Harmonization (ICH), “Stability Testing of New Drug Substances and Products,” ICH Topic Q1A (R2), ICH Secretariat, Geneva, 2005.
|
[8]
|
International Conference on Harmonization (ICH), “Photostability Testing of New Drug Substances and Products,” ICH Q1B Guidline, ICH Secretariat, Geneva, 2005.
|
[9]
|
S. W. Baertschi, K. Alsante and R. A. Reed, “Pharmaceutical Stress Testing: Predicting Drug Degradation,” Drugs and the Pharmaceutical Sciences, Vol. 153, 2005, pp. 1-482. doi:10.1201/9780849359194.ch3
|
[10]
|
US FDA guidance, “Analytical Procedures and Methods Validation,” Food and Drug Administration, Rockville, 2000.
|
[11]
|
The United States Pharmacopeial Convention, “Validation of Compendial Methods <1225>,” The United States Pharmacopeia, Rockville, 2009.
|
[12]
|
M. E. Swartz and I. S. Krull, “Developing and Validating Stability-Indicating Methods by Michael Swartz and Ira Krull,” LC-GC North America, 2005.
|
[13]
|
International Conference on Harmonization (ICH), “Validation of Analytical Procedures: Text and Methodology,” Q2 (R1), ICH Secretariat, Geneva, 2005.
|
[14]
|
J. Ermer and J. H. McB. Miller, “Method Validation in Pharmaceutical Analysis: A Guide to Best Practice,” Wiley-VCH, enero, 2005.
|
[15]
|
D. M. Bliesner, “Validating Chromatographic Methods: A Practical Guide,” Wiley, Hoboken, 2006, pp.1-304.
|